Prothena Corporation plc (PRTA)
NASDAQ: PRTAHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
PRTA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $435.34M
- EPS (TTM)
- -$0.87
- Dividend yield
- None
- 52-week range
- 7.73 – 11.80
- Day range
- 7.88 – 8.63
- Volume / Avg
- 690.41K / 478.70K
- Beta
- —
- Shares outstanding
- 51.34M
- Next earnings
- Nov 5, 2026
52-week range
PRTA stock today
Shares of Prothena (PRTA) finished higher on Oct 7 at $8.48, a gain of 5.74% or $0.46 per share, versus the S&P 500's 0.22% decline. Shares are 28.1% below their 52-week high of $11.80, set on May 8, 2026 and 9.7% above the 52-week low of $7.73, near the bottom of the past year's range. PRTA is down 11.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 16.6%.
Prothena has posted a net loss over the last twelve months (EPS of -$0.87), so its P/E ratio is not meaningful. Prothena's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Prothena
Company profileProthena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Gene G. Kinney Ph.D.
- Headquarters
- Dublin
- Employees
- 67
- Website
- prothena.com
Analyst forecast
ForecastConsensus (6 analysts)
none
Avg. price target
$21.40+152.36%
- Strong buy 2
- Buy 1
- Hold 2
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.38
Prothena peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ENTXEntera Bio Ltd. | 2.51 | -0.79% | $436.32M | vs PRTA |
| SPRYARS Pharmaceuticals Inc. | 4.36 | +1.51% | $433.59M | vs PRTA |
| AGMBAgomAb Therapeutics NV ADR | 8.80 | -0.45% | $433.38M | vs PRTA |
| DMACDiaMedica Therapeutics Inc. | 7.99 | -1.72% | $430.87M | vs PRTA |
| TECXTectonic Therapeutic Inc. | 22.71 | +1.34% | $443.97M | vs PRTA |
| RZLTRezolute Inc. | 4.38 | +1.39% | $423.64M | vs PRTA |
| EDITEditas Medicine Inc. | 2.75 | +0.73% | $422.35M | vs PRTA |
| YDESYD Bio Limited | 5.88 | -4.39% | $416.49M | vs PRTA |
Indexes, lists and sector
Appears in lists
Prothena stock FAQ
What is Prothena's stock price today?
PRTA last traded at $8.48 as of Oct 7, 4:00 PM EDT, up 5.74% on the day. Prices are delayed at least 15 minutes.
When is Prothena's next earnings date?
Prothena is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.38.
Who is Prothena's CEO?
Dr. Gene G. Kinney Ph.D. is the chief executive officer of Prothena Corporation plc, which has about 67 employees.
What is the PRTA 52-week high?
The 52-week high for PRTA is $11.80 and the 52-week low is $7.73. The stock is currently 28.1% below its high.